Keros Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Keros Therapeutics (KROS).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

6Buy

7Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$26Upside to Avg. PT+131.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 4, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$20→$18
Aug 4, 2026	Leerink Partners	—	PT Cut	Outperform	$30→$23
Mar 5, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$23→$20
Nov 28, 2025	B of A Securities	Jason Zemansky	PT Raise	Neutral	$18→$19
Nov 12, 2025	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$23→$27
Nov 11, 2025	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$26→$23
Nov 6, 2025	Wedbush	Yun Zhong	PT Raise	Neutral	$15→$16
Aug 8, 2025	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$25→$20
Jun 10, 2025	B of A Securities	Jason Zemansky	Downgrade	Buy→Neutral	$32→$18
May 30, 2025	Wedbush	Yun Zhong	Maintained	Neutral	$15
May 12, 2025	Scotiabank	Greg Harrison	PT Cut	Sector Outperform	$41→$26
May 8, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$40→$25
Apr 9, 2025	Truist Securities	Srikripa Devarakonda	PT Cut	Buy	$43→$25
Apr 1, 2025	Wedbush	Yun Zhong	Maintained	Neutral	$15
Apr 1, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$40
Feb 27, 2025	Wells Fargo	Tiago Fauth	PT Cut	Overweight	$28→$26
Feb 27, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$47→$40
Jan 21, 2025	Cantor Fitzgerald	Prakhar Agrawal	Downgrade	Overweight→Neutral	—
Jan 17, 2025	Piper Sandler	Joseph Catanzaro	PT Cut	Overweight	$40→$15
Jan 17, 2025	Wedbush	Andreas Argyrides	Downgrade	Outperform→Neutral	$47→$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

B of A Securities analyst Jason Zemansky maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $18 to $19.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

Oppenheimer analyst Andreas Argyrides reiterates Keros Therapeutics (NASDAQ:KROS) with a Outperform and raises the price target from $23 to $27.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $26 to $23.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16

Wedbush analyst Yun Zhong maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $15 to $16.

Benzinga Newsdesk

Keros Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Keros Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

PRO
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

PRO
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

PRO
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16

People Also Watch

People Also Watch

Keros Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Keros Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

PROWells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

PROB of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

PROOppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

PROWells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

PROWedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

PRO
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

PRO
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

PRO
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

PRO
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16